Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population.
about
Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virusPredicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Study of Body Composition and Metabolic Parameters in HIV-1 Male Patients.Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV.Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy.Mind the gap: difference between Framingham heart age and real age increases with age in HIV-positive individuals-a clinical cohort studyThe individual and combined influence of HIV and hepatitis C virus on dyslipidaemia in a high-risk Hispanic population.Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian Positive & Peers Longevity Evaluation Study (APPLES).Management of immunosuppression and antiviral treatment before and after heart transplant for HIV-associated dilated cardiomyopathy.HIV-related chronic obstructive pulmonary disease. Are lung CD4 T cells bothered?Human Immunodeficiency Virus Infection And Hypertension. Is There A Connection?High rates of hypertension, diabetes, elevated low-density lipoprotein cholesterol, and cardiovascular disease risk factors in HIV-infected patients in Malawi.Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro
P2860
Q26851535-58C9E0ED-F21E-407C-BBB0-6ADA8AB81FEFQ30573969-AE5AB187-FCCD-4F07-9D37-B1C28BD0C335Q33804247-E8AAAF97-F2C8-4451-A548-6782F6AF8C2DQ35846104-7915266E-4AB7-4C32-8E91-9B39A813AE9AQ36496736-A63836BA-E85E-4037-B03C-615BAE1952AAQ37256483-D9E58F1E-2752-4E40-8D15-693B2016F24CQ37436597-0F08BEC3-6F84-4B74-806A-C2D0C1D77FB5Q40060225-B142D54D-0DE6-4974-A4B1-7341B15B7ED8Q43584691-4ACB814F-E542-485B-930A-B1FDEA8D1B8CQ44018086-779874A4-3421-4782-B29F-70B6ED61BBCDQ45323599-0F41028F-80D6-4CD0-A4CF-A7279FEA8ACCQ46160196-B346D30E-2B41-485F-8C2A-7933F4AC68F9Q46611261-705EC1AD-0D1E-4AAE-AE48-D843D2C13E95Q57166290-8941EBB5-ED08-4643-AB1A-F0305C2B6533
P2860
Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Cardiovascular disease risk fa ...... an HIV-positive UK population.
@en
Cardiovascular disease risk fa ...... an HIV-positive UK population.
@nl
type
label
Cardiovascular disease risk fa ...... an HIV-positive UK population.
@en
Cardiovascular disease risk fa ...... an HIV-positive UK population.
@nl
prefLabel
Cardiovascular disease risk fa ...... an HIV-positive UK population.
@en
Cardiovascular disease risk fa ...... an HIV-positive UK population.
@nl
P2093
P2860
P1433
P1476
Cardiovascular disease risk fa ...... an HIV-positive UK population.
@en
P2093
P2860
P356
10.1111/J.1468-1293.2004.00191.X
P577
2004-03-01T00:00:00Z